A Prospective Study: Sintilimab and R-CHOP in PMBCL Treatment

Inclusion Criteria: * Pathological diagnosis of PMBCL , and did not receive any previous treatment for PMBCL ; * Predicted survival time ≥ 6 months ; * 18-75 years ; * IPI score 0-3； * ECOG performance status 0-2 ; * Clinicians judge that the patient is suitable for the treatment of primary mediastinal large B-cell lymphoma ; * After the patient was enrolled in the trial, other drugs that may have therapeutic effects on primary mediastinal large B-cell lymphoma were not acceptable ; * WBC ≥ 3 × 109 / L, NE ≥ 1.5 × 109 / L, PLT ≥ 100 × 109 / L ; * Serum creatinine ≤ 1.5mg / dL, creatinine clearance rate ≥ 50mL / min ; * ALT, AST ≤ 3 × ULN ( normal upper limit ) ; total bilirubin ≤ 2 × ULN ; * Sign the informed consent. Exclusion Criteria: * Other malignant diseases except PMBCL were diagnosed within 5 years；·Participating in other interventional clinical studies, or has received chemotherapy, radiotherapy, immunotherapy or biotherapy for lymphoma； * Known allergies to test drugs or any excipient component of these products；·Allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation has been performed； * Women in pregnancy or lactation； * Severe infectious diseases, such as HIV infection, untreated active hepatitis B, active hepatitis C； * The researchers believe that there are other potential risks that are not suitable for participation in this study.